180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is noting a significant milestone reached in a key clinical trial designed to evaluate anti-tumor necrosis factor (“TNF”) for patients with early-stage, pain predominant frozen shoulder. The company announced that the first patient has been randomized in the trial, which is funded by UK-based National Institute of Health and Care Research (“NIHR”); the trial will investigate whether injections of anti-TNF during the early stages of frozen shoulder can reduce or prevent progression of the disease. Sponsored by the University of Oxford, the trial is being led by Professors Sally Hopewell and Jagdeep Nanchahal, who is a consultant for 180 Life Sciences. According to the announcement, 180 Life Sciences has the rights for advancing these studies and commercialization of the trial results. The announced also noted that Sir Marc Feldmann, executive cochair of 180 Life Sciences, is widely recognized for his pioneering work leading up to the first successful use of anti-TNF for treating intractable rheumatoid arthritis; Feldmann observed that anti-TNF has been one of the most successful drug classes of all time, and he is pleased that the company is developing new uses for anti-TNF and conducting clinical trials to fulfil unmet needs that anti-TNF can “ameliorate.” Frozen shoulder is a common condition, affecting an estimated 9% of adults. “Recruiting the first patient for the trial of anti-TNF therapy in frozen shoulder patients is a significant milestone,” said 180 Life Sciences CEO James Woody, MD, in the press release. “Treatment with anti-TNF at the early stage could improve pain and subsequently reduce disability for frozen shoulder patients.”

To view the full press release, visit https://ibn.fm/FnglJ

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s primary platform is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.